Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Previously Presented) A combination composition comprising:

an extrudable fragmented biocompatible resorbable single phase aqueous colloid which is substantially free from a free aqueous phase, said single phase aqueous colloid being present in an applicator having an extrusion orifice, wherein the single phase aqueous colloid has been fragmented by mechanical disruption, comprises a cross-linked gelatin polymer present in discrete subunits, has an equilibrium swell from 400% to 5000%, and has at least one characteristic selected from the group consisting of (a) a subunit size when fully hydrated in the range from 0.01 mm to 5 mm, and (b) an *in vivo* degradation time of less than one year; and

a non-cross-linked gelatin polymer,

wherein the discrete subunits of the cross-linked gelatin polymer provide void areas which are filled with the non-cross-linked gelatin polymer, and

wherein the cross-linked gelatin polymer and the non-cross-linked gelatin polymer are present in the combination in a weight ratio within a range from 5:1 to 2:1.

2-18. (Canceled)

19. (Previously Presented) The combination composition of claim 1, wherein the single phase aqueous colloid has a subunit size when fully hydrated in the range from 0.01 mm to 5 mm.

20. (Canceled)

21. (Previously Presented) The combination composition of claim 1, wherein the single phase aqueous colloid has an *in vivo* degradation time of less than one year.

22-23. (Canceled)

24. (Previously Presented) The combination composition of claim 1, wherein the single phase aqueous colloid has a subunit size when fully hydrated in the range from 0.01 mm to 5 mm and an *in vivo* degradation time of less than one year.

25. (Previously Presented) The combination composition of claim 1, said single phase aqueous colloid being at least partially hydrated with an aqueous medium comprising an active agent.

26. (Previously Presented) The combination composition of claim 25, wherein the active agent is a clotting agent.

27. (Previously Presented) The combination composition of claim 26, wherein the clotting agent is thrombin.

28-29. (Canceled)

30. (Previously Presented) The combination composition of claim 27, wherein the single phase aqueous colloid further comprises a polysaccharide.

31. (Previously Presented) The combination composition of claim 27, wherein the single phase aqueous colloid further comprises a non-biological polymer.

32. (Previously Presented) The combination composition of claim 27, wherein the single phase aqueous colloid further comprises a polysaccharide or a non-biological polymer, or both.

33. (Canceled)

34. (Previously Presented) A combination composition comprising:

an extrudable fragmented biocompatible resorbable single phase aqueous colloid, wherein the single phase aqueous colloid has been fragmented by mechanical disruption, is not hydrated above its capacity to absorb water, has an equilibrium swell from 400% to 5000%, and comprises cross-linked gelatin present in discrete subunits, the single phase aqueous colloid having at least one characteristic selected from the group consisting of (a) a subunit size when fully hydrated in the range from 0.01 mm to 5 mm and (b) an *in vivo* degradation time of less than one year; and

a non-cross-linked polymeric material,

wherein the cross-linked gelatin and the non-cross-linked polymeric material are present in an applicator having an extrusion orifice,

wherein the discrete subunits of the cross-linked gelatin provide void areas which are filled with the non-cross-linked polymeric material, and

wherein the cross-linked gelatin and the non-cross-linked polymeric material are present in the combination in a weight ratio within a range from 5:1 to 2:1.

35. (Previously Presented) A combination composition comprising:

an extrudable fragmented biocompatible resorbable single phase aqueous colloid which is substantially free from a free aqueous phase, wherein the single phase aqueous colloid has been fragmented by mechanical disruption, has an equilibrium swell from 400% to 5000%, and comprises a cross-linked protein present in discrete subunits and a polysaccharide, the single phase aqueous colloid having at least one characteristic selected from the group consisting of (a) a subunit size when fully hydrated in the range from 0.01 mm to 5 mm and (b) an *in vivo* degradation time of less than one year; and

a non-cross-linked polymeric material,

wherein the cross-linked protein and the non-cross-linked polymeric material are present in an applicator having an extrusion orifice, and

wherein the discrete subunits of the cross-linked protein provide void areas which are filled with the non-cross-linked polymeric material.

36. (Previously Presented) A combination composition comprising:

an extrudable fragmented biocompatible resorbable single phase aqueous colloid which is substantially free from a free aqueous phase, wherein the single phase aqueous colloid has been fragmented by mechanical disruption, has an equilibrium swell from 400% to 5000%, and comprises a cross-linked protein present in discrete subunits and a non-biological polymer, the single phase aqueous colloid having at least one characteristic selected from the group consisting of (a) a subunit size when fully hydrated in the range from 0.01 mm to 5 mm and (b) an *in vivo* degradation time of less than one year; and

a non-cross-linked polymeric material,

wherein the cross-linked protein and the non-cross-linked polymeric material are present in an applicator having an extrusion orifice, and

wherein the discrete subunits of the cross-linked protein provide void areas which are filled with the non-cross-linked polymeric material.

37. (New) A device consisting of:

a syringe; and

an amount of a resorbable fragmented cross-linked gelatin gel present in the syringe, wherein the gel biodegrades in a patient's body in a time period ranging from 1 to 90 days.

38. (New) The device according to Claim 37, wherein the gel biodegrades in a patient's body in a time period ranging from 2 to 30 days.

39. (New) The device according to Claim 37, wherein the gel resorbs in a time period ranging from 14 to 60 days.

40. (New) A device consisting of:

a syringe;

an amount of a resorbable fragmented cross-linked gelatin gel present in the syringe, wherein the gel biodegrades in a patient's body in a time period ranging from 1 to 90 days; and

a bioactive component.

41. (New) The device according to Claim 40, wherein the bioactive component is a hemostatic agent.

42. (New) The device according to Claim 41, wherein the hemostatic agent is thrombin.

43. (New) The device according to Claim 42, wherein the gel comprises 500 to1000 units thrombin/ml gel.

44. (New) A composition of matter comprising:

a sterile package; and

a device according to Claim 37 present inside of the sterile package.

45. (New) A device consisting of:

a syringe; and

an amount of a resorbable fragmented partially hydrated cross-linked gelatin gel present in the syringe.

46. (New) The device according to Claim 45, wherein the gel has an equilibrium swell ranging from 400% to 1300%.

47. (New) The device according to Claim 46, wherein the gel has an equilibrium swell ranging from 500% to 1100%.

48. (New) The device according to Claim 47, wherein the gel biodegrades in a patient's body in a time period ranging from 1 to 90 days.

49. (New) The device according to Claim 45, wherein the gel biodegrades in a patient's body in time period ranging from 2 to 30 days.

50. (New) The device according to Claim 45, wherein the gel resorbs in a time period ranging from 14 to 60 days.

51. (New) A device consisting of:

a syringe; and

an amount of a resorbable fragmented cross-linked gelatin gel present in the syringe wherein the gel has an equilibrium swell from 400% to 1300%.

52. (New) The device according to Claim 51, wherein the gel has an equilibrium swell ranging from 500% to 1100%.

53. (New) The device according to Claim 51, wherein the gel biodegrades in a patient's body in a time period ranging from 1 to 90 days.

54. (New) The device according to Claim 51, wherein the gel biodegrades in a patient's body in time period ranging from 2 to 30 days.

55. (New) The device according to Claim 51, wherein the gel resorbs in a time period ranging from 14 to 60 days.

56. (New) The device according to Claim 51, wherein the gel comprises a bioactive component.

57. (New) The device according to Claim 56, wherein the bioactive component is a hemostatic agent.

58. (New) The device according to Claim 56, wherein the hemostatic agent is thrombin.

59. (New) The device according to Claim 58, wherein the gel comprises 100 to1000 units thrombin/ml gel.

60. (New) A kit comprising:

a device according to either Claim 45 or Claim 51; and

a tray.

61. (New) The kit according to Claim 60, wherein the kit further comprises a container comprising an aqueous medium.

62. (New) The kit according to Claim 61, wherein the kit further comprises thrombin.

63. (New) A method comprising:

(a) providing a device consisting of:

(i) a syringe; and

(ii) an amount of a resorbable fragmented cross-linked gelatin gel present in the syringe, wherein the gel biodegrades in a patient's body in a time period ranging from 1 to 90 days; and

(b) delivering the gel from the syringe to a patient.